Posts tagged ‘ASCO’
Last week the hot news was the anticipated FDA approval of vemurafenib (Zelboraf™) in metastatic melanoma for patients with BRAF V600E mutations.
Sally Church on Pharma Strategy Blog has written extensively about new products in development for metastatic melanoma. As Sally notes in her recent blog post discussing the Zelboraf™ approval:
“the good news is that oncologists now have two new agents for treatment in 2011, which is very much a grand cru year for melanoma.”
A little known fact is that Sally is a former finalist in the UK Daily Telegraph newspaper’s wine taster of the year competition, so it is perhaps not surprising to see some wine references in her writing.
If you are interested in the price of Zelboraf™ – you can find it on Pharma Strategy Blog where Sally analyses the cost of a course of treatment and compares this to the price for ipilimumab.
Pieter Droppert’s write-up of the 2011 ASCO annual meeting plenary data on metastatic melanoma was recently published in the august issue of Pharmacy Today.
I tweet therefore I am! Sally Church who has a lot of experience in pharma social media, was recently featured in the May 31st bulletin of the National Cancer Institute (NCI).
In an excellent article by Edward Winstead, entitled “Scientific Meetings through the Lens of Twitter”, Sally is quoted on how Twitter has been used to share information at the recent 2011 annual meetings of the American Association for Cancer Research (AACR) and American Urological Association (AUA).
With multiple scientific sessions taking place in parallel at conferences, live-tweets from participants do allow you to follow what is happening elsewhere, and indeed may stimulate you to change session (to a more interesting one).
If you can’t be present at a meeting, following the conference on twitter, gives you insight into some of the key messages. However, there’s only so much that can be said in 140 characters, so tweets are not likely to replace more in-depth blog posts. Also, like listening in on a conversation, what is tweeted cannot necessarily be relied upon.
Sally will be live-tweeting from the forthcoming 2011 annual meeting of the American Society of Clinical Oncology. She will also be aggregating, on Pharma Strategy Blog, the tweets of others who are using the hashtag #ASCO11. ”Check it out!” as Sally would say.
Photo Credit: Nimesh Madhaven
This Friday sees the start of the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The meeting runs from June 3-7.
On Pharma Strategy Blog, Sally Church shares her thoughts on what she expects to be hot news at ASCO this year.
In her ASCO11 video preview Sally discusses clinical trial presentations in ovarian cancer, metastatic melanoma and soft tissue sarcoma. You can watch Sally’s video below and read more on Pharma Strategy Blog.
Icarus Consultants will be attending ASCO (along with 30,000 others), so if you are interested in meeting up, please contact us.
Understanding the biology of Chronic Lymphocytic Leukemia (CLL) & indolent B-cell lymphoma
April 15th, 2011
Daedalus
In order to understand the mechanism of action (MOA) of a drug, you first have to know the underlying biology of the disease. This is particularly important for new products, where you are often analyzing how you compare to competitors, and the strengths and weaknesses each may have in their MOA.
In anticipation of new data at the forthcoming American Society of Clinical Oncology (ASCO) meeting, Sally Church on Pharma Strategy Blog provides a review of two hematologic malignancies, indolent B-cell lymphoma and chronic lymphocytic leukemia (CLL).
In Sally’s post, she applies what we know about the underlying science to current drug therapies. One of her conclusions is that FCR (fludarabine, cyclophosphamide, rituximab) “is now very much the bedrock of treatment for patients with CLL and is based on a very solid rationale.”
For those interested in what new therapies are emerging for CLL, you’ll have to read further on Pharma Strategy Blog.
Sally is a regular attendee at the annual meetings of the American Society of Hematology (ASH) and ASCO, and has particular expertise in this area. Please feel free to contact us to find out how we can help you bring new hematology products to market.
We are excited to hear that Sally Church has produced another video to follow on from her recent video debut on Pharma Strategy Blog.
Produced by the aptly named, “PSB Films”, it is a trailer for her eagerly awaited post on “What’s hot at AACR 2011?”
Readers of Sally’s blog will know that prior to major scientific meetings such as AACR, ASCO and ASH, Sally often provides a mixture of commentary and insight on what she predicts will be hot topics.
Happy April 1st!
Many European doctors enjoy a glass of good wine, so Bertrand Tombal’s metaphor that 2010 was a great year for advanced prostate cancer drugs was well received at the recent European Association of Urology Congress in Vienna.
Sally Church attended the meeting, and shared her thoughts on “the changing face of advanced prostate cancer” in a post on Pharma Strategy Blog.
According to Sally, one of the highlights of the meeting was the plenary presentation by Professor Johann de Bono of the Royal Marsden in the UK who discussed the new products that now exist or will soon be available for advanced prostate cancer.
Professor de Bono described how we now know more about Prostate Cancer and the fact that androgen receptor signaling remains active in advanced prostate cancer. Hormone therapy now works after chemotherapy, so the use of the term metastatic hormone refractory mHRPC is no longer valid.
He predicted that the we can expect the prostate cancer field to change in the next few years as we learn more about the molecular aspects of the disease and are better able to stratify patients.
With new products such as abiraterone, MDV3100 on the horizon and recent approvals for cabazitaxel, sipuleucel-T, multiple lines of treatment will be available to patients. The challenge according to Professor de Bono will be how to sequence them.
Further news on new product development in prostate cancer can be expected at AUA, ASCO and ESMO. With approval for abiraterone expected later this year, 2011 may be a Grand Cru year too! You can keep track of the latest developments in this market on Pharma Strategy Blog.
It’s that time of year, when the prospect of an escape from New Jersey to Florida for some sunshine is quite appealing to all in the pharma industry.
ASCO Genitourinary (GU) 2011 starts this week in Orlando, and Sally Church from Icarus Consultants will be at the meeting.
From the number of flyers for educational symposia we’ve received, prostate cancer looks to be a hot topic, and some new data appears likely.
If you are attending, do say hello to Sally or invite her for a coffee (or something stronger).
Published by Pieter Droppert on Biotech Strategy Blog